QUINCE THERAPEUTICS INC (QNCX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$31.32+2.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · QNCX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress LAM-001 through multiple clinical trials including Phase 2b in PH-ILD, Phase 2 in BOS, and Phase 2 in SAPH with data readouts planned through 2028.
Stated in 2 of last 2 quarters. Management outlined advancing LAM-001 through Phase 2b trial in PH-ILD with data expected Q1 2028, Phase 2 data in BOS expected Q1 2027, and a Phase 2 study in SAPH planned for late 2026. These milestones remain on track with no revenue reported yet, consistent with clinical-stage development status.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Advancing LAM-001 through multiple clinical milestones including Phase 2b trial in PH-ILD and Phase 2 data in BOS.”
“LAM-001 Phase 2b study in PH-ILD anticipated to begin mid-2026 with data in Q1 2028.”
Finalize the acquisition of Orphai Therapeutics and integrate its assets including LAM-001 into Quince's pipeline.
Stated in 2 of last 2 quarters. The acquisition of Orphai was completed on May 18, 2026, as confirmed by management. This strategic growth priority has been delivered with integration of Orphai's LAM-001 program into Quince's pipeline.
“Acquisition of Orphai completed and integrated into Quince's pipeline.”
“Announced acquisition of Orphai and planned integration of LAM-001 program.”
Use proceeds from private placement and existing cash to fund operations and clinical milestones through 2028.
Stated in 2 of last 2 quarters. Management expects the $115.98 million cash and cash equivalents as of 2026-Q2, combined with private placement proceeds, to fund operations through end of 2028. This aligns with the stated cash runway priority and shows delivery on capital allocation plans.
“Cash and cash equivalents at closing expected to fund operations through end of 2028.”
“Upfront proceeds and existing cash expected to fund operations through 2028.”
Implement reverse stock split and other measures to regain compliance with Nasdaq listing standards.
Stated in 2 of last 2 quarters. Management executed a 1-for-20 reverse stock split effective June 29, 2026, as part of efforts to regain Nasdaq compliance. Despite this, the company received a delisting notice in 2026-Q3, indicating ongoing regulatory challenges.
“Reverse stock split of 1-for-20 effective June 29, 2026, to meet Nasdaq requirements.”
“Plan to implement reverse stock split to address Nasdaq listing standards.”
Consider strategic options and potential restructuring to enhance company value and operational efficiency.
Over the trailing year it converted -38.14x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
19 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.